A detailed history of Ubs Group Ag transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 364,172 shares of SRPT stock, worth $40.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
364,172
Previous 350,764 3.82%
Holding current value
$40.4 Million
Previous $55.4 Million 17.93%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$124.33 - $156.75 $1.67 Million - $2.1 Million
13,408 Added 3.82%
364,172 $45.5 Million
Q2 2024

Aug 13, 2024

BUY
$113.33 - $163.85 $8.34 Million - $12.1 Million
73,574 Added 26.54%
350,764 $55.4 Million
Q1 2024

May 13, 2024

BUY
$93.7 - $141.53 $85,641 - $129,358
914 Added 0.33%
277,190 $35.9 Million
Q4 2023

Feb 09, 2024

BUY
$67.31 - $124.76 $3.26 Million - $6.04 Million
48,405 Added 21.24%
276,276 $26.6 Million
Q3 2023

Nov 09, 2023

BUY
$102.5 - $123.59 $1.18 Million - $1.43 Million
11,531 Added 5.33%
227,871 $27.6 Million
Q2 2023

Aug 11, 2023

BUY
$106.4 - $157.19 $2.33 Million - $3.45 Million
21,918 Added 11.27%
216,340 $24.8 Million
Q1 2023

May 12, 2023

BUY
$117.53 - $155.99 $3.73 Million - $4.95 Million
31,742 Added 19.51%
194,422 $26.8 Million
Q4 2022

Feb 08, 2023

BUY
$100.86 - $132.13 $9.27 Million - $12.1 Million
91,942 Added 129.98%
162,680 $21.1 Million
Q3 2022

Nov 10, 2022

SELL
$75.71 - $119.24 $3.5 Million - $5.51 Million
-46,200 Reduced 39.51%
70,738 $7.82 Million
Q2 2022

Aug 10, 2022

SELL
$62.69 - $88.44 $2.25 Million - $3.18 Million
-35,935 Reduced 23.51%
116,938 $8.77 Million
Q1 2022

May 16, 2022

BUY
$63.15 - $90.42 $5.7 Million - $8.16 Million
90,229 Added 144.03%
152,873 $11.9 Million
Q4 2021

Feb 14, 2022

BUY
$77.28 - $99.42 $1.23 Million - $1.58 Million
15,913 Added 34.05%
62,644 $5.64 Million
Q3 2021

Nov 15, 2021

BUY
$65.97 - $92.48 $844,152 - $1.18 Million
12,796 Added 37.71%
46,731 $4.32 Million
Q2 2021

Aug 13, 2021

SELL
$69.38 - $86.75 $3.7 Million - $4.62 Million
-53,265 Reduced 61.08%
33,935 $2.64 Million
Q1 2021

May 12, 2021

BUY
$72.25 - $168.95 $1.12 Million - $2.61 Million
15,450 Added 21.53%
87,200 $6.5 Million
Q4 2020

Feb 11, 2021

BUY
$125.56 - $178.74 $614,616 - $874,932
4,895 Added 7.32%
71,750 $12.2 Million
Q3 2020

Nov 12, 2020

BUY
$127.12 - $172.34 $252,968 - $342,956
1,990 Added 3.07%
66,855 $9.39 Million
Q2 2020

Jul 31, 2020

SELL
$93.0 - $171.7 $1.75 Million - $3.23 Million
-18,799 Reduced 22.47%
64,865 $10.4 Million
Q1 2020

May 01, 2020

SELL
$82.38 - $131.64 $273,089 - $436,386
-3,315 Reduced 3.81%
83,664 $8.18 Million
Q4 2019

Feb 14, 2020

SELL
$76.53 - $135.58 $8.28 Million - $14.7 Million
-108,252 Reduced 55.45%
86,979 $11.2 Million
Q3 2019

Nov 14, 2019

BUY
$72.81 - $156.91 $6.25 Million - $13.5 Million
85,870 Added 78.52%
195,231 $14.7 Million
Q2 2019

Aug 14, 2019

BUY
$112.21 - $151.95 $3.25 Million - $4.4 Million
28,958 Added 36.02%
109,361 $16.6 Million
Q1 2019

May 14, 2019

SELL
$106.67 - $151.68 $477,028 - $678,312
-4,472 Reduced 5.27%
80,403 $9.58 Million
Q4 2018

Feb 14, 2019

BUY
$97.32 - $148.76 $2.23 Million - $3.41 Million
22,929 Added 37.01%
84,875 $9.26 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $3.33 Million - $4.66 Million
-28,870 Reduced 31.79%
61,946 $10 Million
Q2 2018

Aug 14, 2018

SELL
$71.74 - $153.69 $1.23 Million - $2.64 Million
-17,148 Reduced 15.88%
90,816 $12 Million
Q1 2018

May 15, 2018

BUY
$54.02 - $82.27 $1.6 Million - $2.43 Million
29,550 Added 37.68%
107,964 $8 Million
Q4 2017

Feb 14, 2018

SELL
$47.64 - $56.75 $2.69 Million - $3.2 Million
-56,400 Reduced 41.84%
78,414 $4.36 Million
Q3 2017

Nov 14, 2017

BUY
$35.73 - $47.15 $1.26 Million - $1.67 Million
35,317 Added 35.5%
134,814 $6.12 Million
Q2 2017

Aug 14, 2017

BUY
N/A
18,053 Added 22.17%
99,497 $3.35 Million
Q1 2017

Nov 14, 2017

BUY
N/A
81,444
81,444 $2.41 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.71B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.